New Zealand markets closed

Wuhan YZY Biopharma Co., Ltd. (2496.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
7.4500.000 (0.00%)
At close: 03:46PM HKT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
Total revenue
0
0
0
0
Operating expenses
Research development
155,054
155,054
157,329
112,893
Selling general and administrative
22,311
22,311
20,525
8,874
Total operating expenses
190,050
190,050
187,375
134,967
Operating income or loss
-190,050
-190,050
-187,375
-134,967
Interest expense
2,388
2,388
2,468
14,972
Income before tax
-191,702
-191,702
-188,866
-148,518
Income tax expense
0
0
0
0
Income from continuing operations
-191,702
-191,702
-188,866
-148,518
Net income
-191,702
-191,702
-188,866
-148,518
Net income available to common shareholders
-191,702
-191,702
-188,866
-148,518
Basic EPS
-0.98
-
-0.98
-0.77
Diluted EPS
-0.98
-
-0.98
-0.77
Basic average shares
193,001
-
193,001
193,001
Diluted average shares
193,001
-
193,001
193,001